AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05185661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth education
Description: eHealth education intervention regarding the dietary plan, healthy-lifestyle, and hygiene:~1. Group-wise eHealth education through online PowerPoint presentation session among study participants with their guardian: Two times (Before starting the intervention and mid-line; end of 4th-month intervention)~2. eHealth education through phone calls \& SMS~   * 1st to 4th month: 4 times in a month~  * 5th to 6th month: 3 times in a month~  * 6th to 8th month: 2 times in a month~3. Control group will not get care and education
Study NCT06210217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine hydrochloride, Injectable
Description: In the dobutamine group, 3\~6μg/kg/min dobutamine will be injected intravenously after anesthesia induction until hemostasis is completed. The dose of dobutamine will be increased if the operating field grade exceeds Grade II. Monitoring LVEDV and SV with TEE to ensure preload: after admission, the patient will be given 3-4 mL /kg/h equilibrium fluid as background infusion. LVEDV and SV will be monitored using TEE every 30 minutes after anesthesia induction. If LVEDV\<75mL or SV\<45mL, 200mL colloidal fluid will be given within 5min.
Study NCT06210217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: In the control group, 3mL/h normal saline will be injected intravenously after anesthesia induction until hemostasis is completed. According to the currently commonly used principle of LCVP, the fluid will be limited to 3-4 ml /kg/h after anesthesia induction. If the operating field grade exceeds Grade II, nitroglycerin will be injected intravenously for remedial purposes at a rate of 0.3-0.8μg/kg/min.
Study NCT06373952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online to offline counseling
Description: * Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment.
Study NCT06373952 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online to offline counseling
Description: * Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment.
Study NCT06282978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab (PF-06863135)
Description: The scheme of administration includes weekly administrations for at least six 4-weeks cycles and, if patients have achieved at least PR (or better) persisting for at least 2 months, the dose interval should be changed from weekly to every other week. Treatment will be scheduled with a response-adapted duration and patients achieving undetectable measurable residual disease (MRD) and maintained for 12 months will stop therapy. After stopping therapy, and if the patient is in sustained undetectable MRD for at least 12 months, it would be possible to re-start treatment with elranatamab in case the MRD will be detectable or relapse from CR will occur. Patients who will not achieve undetectable MRD sustained for 12 months will receive continuous treatment until progressive disease.
Study NCT04816552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHoBI7 mHealth program Arm
Description: We will start delivery of this intervention with a pictorial module delivered in the home during two 30 minute visits on cholera transmission and prevention after enrollment. Households will be provided a handwashing station, a covered water vessel, and chlorine tablets. Households will then receive the CHoBI7 WASH mHealth program voice and text messages on handwashing with soap and water treatment bi-weekly.
Study NCT04816552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: general message on oral rehydration solution (ORS)
Description: general message on oral rehydration solution (ORS)
Study NCT04816552 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general message on oral rehydration solution (ORS)
Description: general message on oral rehydration solution (ORS)
Study NCT05434416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app
Description: mobile app self-guided psychological interventions
Study NCT05862649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuraLight
Description: NeuraLight software-based platform
Study NCT05305404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: 1.5mg oral dexamethasone to be administered once at 11:00PM
Study NCT05305404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo to be administered once at 11:00PM
Study NCT05808829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Exercise
Description: University students did progressive muscle relaxation exercises at least 4 times a week for 6 weeks. Once a week, exercise was done with the researcher by online interview via Zoom.
Study NCT05004441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib Combined With mFOLFOX6/FOLFIRI
Description: Fruquintinib (3mg) will be given p.o. daily
Study NCT00751517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT00751517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT06255431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezerra cream
Description: The research subjects were divided into 2 groups: group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face).~The test material consists of a cream containing a mixture of spent grain wax extract, shea butter, and argan oil, along with a vehicle cream. Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.The creams are applied to the face twice daily (0,5 FTU), immediately after washing, in equal amounts on each side of the face. The creams are applied for 7 days, and participants are instructed to use appropriate sunscreen.
Study NCT06255431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezerra cream
Description: The research subjects were divided into 2 groups: group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face).~The test material consists of a cream containing a mixture of spent grain wax extract, shea butter, and argan oil, along with a vehicle cream. Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.The creams are applied to the face twice daily (0,5 FTU), immediately after washing, in equal amounts on each side of the face. The creams are applied for 7 days, and participants are instructed to use appropriate sunscreen.
Study NCT05542719 — intervention group
Intervention type: OTHER
Intervention: application
Description: Through the application, determine if the patient is out of LDL-C goals for referral and treatment review.~Show the usefulness of the application in achieving dyslipidemia treatment goals in patients with high and extremely high cardiovascular risk
Study NCT05378750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diuretic algorithm
Description: Implementing diuretic algorithm
Study NCT05106400 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ZTlido (Lidocaine Topical System) 1.8%
Description: 1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
Study NCT05106400 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Salonpas (Lidocaine Patch 4%)
Description: 1 Salonpas (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
Study NCT05106400 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspercreme (Lidocaine Patch 4%)
Description: 1 Aspercreme (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
Study NCT05106400 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IcyHot (Lidocaine 4% + Menthol 1% Patch)
Description: 1 IcyHot (Lidocaine 4% + Menthol 1% Patch) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
Study NCT05670886 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine artery ligation
Description: The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally Lower uterine incision was done followed by fetal extraction and placental delivery . bilateral uterine artery ligation were done 2cm below the uterine incision.
Study NCT05670886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine artery ligation
Description: The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally Lower uterine incision was done followed by fetal extraction and placental delivery . bilateral uterine artery ligation were done 2cm below the uterine incision.
Study NCT04727307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (neoadjuvant)
Description: Atezolizumab 1200mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in neoadjuvant, for 2 cycles. The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 (± 10) minutes.
Study NCT04727307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Radiofrequency
Description: Any RFA system (uni/multi-needle, monopolar or multi-bi-polar) is allowed. Microwave ablation or irreversible electroporation is not allowed.
Study NCT04727307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Radiofrequency
Description: Any RFA system (uni/multi-needle, monopolar or multi-bi-polar) is allowed. Microwave ablation or irreversible electroporation is not allowed.
Study NCT04727307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (adjuvant)
Description: Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle in adjuvant, for 15 cycles maximum. The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 (± 10) minutes then over 30 (± 10) minutes.
Study NCT04727307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (adjuvant)
Description: Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in adjuvant, for 15 cycles maximum. The dose will be delivered over 30 (± 10) minutes.
Study NCT05513794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Imaging
Description: Neuromelanin sequence imaging
Study NCT04318353 — intervention group
Intervention type: OTHER
Intervention: early enteral feeding within 2 days postoperative
Description: Enteral feeding within 2 days postoperative
Study NCT05119361 — intervention group
Intervention type: OTHER
Intervention: Early Dry protocol
Description: After meeting eligibility criteria, patients have a net ultrafiltration of 2mL/kg/h with systematic perfusion monitoring (lactate concentration, central venous saturation, mottling score and capillary refill time) and restrictive input.~If the patient presents hypoperfusion (at least to sign), net ultrafiltration is stopped and haemodynamic optimized.~If the patient presents pulmonary oedema or right ventricular failure, with venous congestion, ultrafiltration is set at 3mL/kg/h.~Ultrafiltration is set between 0.5 and 1mL/kg/h when the following criteria are fulfilled: weight inferior to the admission weight; central venous pressure inferior to 5mmHg; absence of clinical oedema.~The haemodynamic status is reevaluated all six hours.
Study NCT04814004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCD19.IL15.CAR-iNKT
Description: Universal hCD19.IL15.CAR-iNKT cells by a single infusion intravenously will be given in escalating doses.
Study NCT05038982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib
Description: During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.
Study NCT05513404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honeyberry
Description: To investigate changes in postprandial glucose and cognitive performance, after consumption of honeyberries grown in Scotland.
Study NCT05513404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry
Description: To investigate changes in postprandial glucose and cognitive performance, after consumption of cherries grown in Scotland.
Study NCT05513404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raspberry
Description: To investigate changes in postprandial glucose and cognitive performance, after consumption of raspberries grown in Scotland.
Study NCT06080841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin. They will be instructed to consume orally 1 capsule with breakfast for group 1, 1 capsule with each meal for group 3, and 2 capsules with each food for group 5.
Study NCT06080841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin + Piperine
Description: Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin additioned with 5 mg of piperine. They will be instructed to consume orally 1 capsule with breakfast for group 2, 1 capsule with each meal for group 4, and 2 capsules with each meal for group 6.
Study NCT05644158 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization
Description: Depending on the exact morphology of the lesion, patients with short superficial femoral artery lesions (\<25 cm) will be subdivided into group 2A with endovascular treatment (percutaneous transluminal angioplasty with or without stenting) and patients with long superficial femoral artery lesions (>25 cm) will be subdivided into group 2B with open surgical treatment (femoropopliteal bypass) .
Study NCT05644158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Home-based monitored exercise training (walking), 3 times a week, monitored with log book and activity sensors.
Study NCT05380817 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Remote Monitoring Program
Description: Participants receive remote monitoring while engaging in a theory-based, multi-component, multi-level, multi-setting (MMM) community team sports program designed specifically for children
Study NCT05005117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic operation
Description: Operation
Study NCT05005117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open operation
Description: Operation
Study NCT05375760 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
Description: Arm A - Day 1:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region.~Arm A - Days 92, 183, 274, 365:~300 mg AZD7442 administered sequentially as a 1.5 mL IM injection containing 150 mg tixagevimab (AZD8895) and a 1.5 mL IM injection containing 150 mg cilgavimab (AZD1061), one injection in each gluteal region.
Study NCT05375760 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
Description: Arm B - Day 1:~1200 mg AZD7442 (600 mg tixagevimab \[AZD8895\] and 600 mg cilgavimab \[AZD1061\]) administered by IV infusion.~Arm B - Days 183, 365:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region.
Study NCT05208099 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood tests
Description: For patients, it will be performed:~* a collection of blood samples (3 tubes of 5 mL) according to the usual medical management, in order to search for cardiovascular comorbidities associated with HS,~* A collection of 3 EDTA tubes and 2 additional dry tubes of 5 mL each according to the needs of the study.
Study NCT05208099 — intervention group
Intervention type: PROCEDURE
Intervention: exeresis
Description: For patients, it will be performed:~- 6 tissue samples from the total excision specimen: two samples from the acute inflammatory zone (nodule, abscess, fistula) of 1 cm3; two samples from the chronic lesion zone (scar) of 1 cm3 and two samples from the peri-lesion zone (in the margin) of 1 cm3 on fresh tissue.
Study NCT05208099 — intervention group
Intervention type: PROCEDURE
Intervention: abdominoplasty
Description: For the controls, 6 fresh skin samples of 1 cm3 each will be taken from the abdominoplasty operation:~* four in the center,~* two in the margin
Study NCT05156034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRK-001
Description: Participants will receive IV doses of SRK-001.
Study NCT05156034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV doses of placebo.
Study NCT05067725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CarePath
Description: During an in-clinic patient encounter with a primary care provider (PCP) in any one of the intervention CMSL sites, the BPA is fired when any type of headache or migraine is entered as a diagnosis or chief complaint. The purpose of the headache assessment questionnaire is to assist the PCP in characterizing patients' headache. The Express Lane will help guide PCP decision-making for prescribing medications, lab/image ordering, and referrals. The Ask-a-doc button will provide timely access to a virtual treatment and diagnosis consult with a neurologist.
Study NCT05064215 — intervention group
Intervention type: PROCEDURE
Intervention: anatomical examination
Description: After injection of dye, its distribution along lymphatic clearance paths was investigated
Study NCT06177548 — intervention group
Intervention type: PROCEDURE
Intervention: Minimally invasive Bentall procedure
Description: The minimally invasive Bentall procedure is performed through a small incision in the right intercostal space.
Study NCT04843462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: edupression.com®
Description: Edupression.com® is an evidence-based self-help program that was developed for the treatment of mild to moderate unipolar depression. It is based on two core foundations, psychoeducation with elements of cognitive behavior therapy (CBT) and a mood chart. Both foundations are registered as a medical product. As such, detailed risk management documentation includes probability and severity of adverse events. Moreover, detailed strategies such as warnings were implemented in the software and documented accordingly.~It can be used on a PC as well as on mobile devices (browser, app) at any time.
Study NCT04843462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray
Description: All patients included in this study are receiving esketamine nasal spray as treatment-as-usual
Study NCT04843462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine nasal spray
Description: All patients included in this study are receiving esketamine nasal spray as treatment-as-usual
Study NCT05342714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 180 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.(Patent No.CN200820123637.X, China).
Study NCT04731558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin or tinzaparin or dalteparin
Description: Thromboprophylaxis initiated approximately 14 hours prior to the planned liver resection skin incision. Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function